Abstract:ID 92269 Poster Board 517 The opioid crisis (e.g., overdose deaths) has worsened significantly during the COVID-19 pandemic, despite a decrease in the number of prescriptions for opioids. However, the number of prescriptions for and the off-label use of gabapentinoids (gabapentin and pregabalin) as alternative medications used for chronic pain is soaring with gabapentinoids increasingly detected in opioid overdose victims, raising serious concerns about the health risks of this class of drugs. The effect of gabapentinoids on mu opioid receptor (MOR)-mediated in vivo activity is not well characterized, although a study in male rats reported that gabapentinoids decrease the potency of the opioid receptor antagonist naloxone to reverse hypoventilation by the morphinan MOR agonist heroin. Male rats (n = 8) discriminating the non-morphinan MOR agonist fentanyl (0.0032 mg/kg, intraperitoneally, i.p.) from saline under a fixed-ratio 10 schedule of food reinforcement, were used to test the following hypotheses: 1) gabapentinoids do not share discriminative stimulus effects with fentanyl; 2) gabapentinoids increase the potency of fentanyl to produce discriminative stimulus effects; and 3) gabapentinoids decrease the potency of naloxone to antagonize the discriminative stimulus effect of fentanyl. Gabapentin (10-320 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) occasioned a maximum average, respectively, of 37.8% and 46.3% fentanyl-appropriate responding, and decreased rates of responding to 6.0% and 7.4% of control. Heroin (0.032-0.1 mg/kg, i.p.) occasioned 100% fentanyl-appropriate responding whereas the stimulant drugs cocaine (0.32-10 mg/kg, i.p.) and d -methamphetamine (0.1-3.2 mg/kg, i.p.) did not increase fentanyl-appropriate responding up to doses that significantly decreased rates of responding. Acute pretreatment with gabapentin (3.2-32 mg/kg, i.p.) or pregabalin (3.2-32 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 17-fold to the left. In contrast, naloxone (0.01-1.0 mg/kg, i.p.) dose-dependently shifted the fentanyl discrimination dose-effect function up to 95-fold to the right. Rightward shifts by naloxone (0.1 and 1.0 mg/kg, i.p.) in the fentanyl discrimination dose-effect function were attenuated dose-dependently by gabapentin (3.2-100 mg/kg, i.p.) and pregabalin (3.2-100 mg/kg, i.p.) up to 63 fold. Similar presession treatment effects of gabapentinoids were observed with heroin. These results suggest that gabapentinoids 1) produce only partial but significant fentanyl-like discriminative stimulus effects, 2) enhance the discriminative stimulus effects of the MOR agonists including the non-morphinan (phenylpiperidine) fentanyl as well as the morphinan heroin, and 3) attenuate naloxone antagonism of the discriminative stimulus effects of the MOR agonists. These results can help guide government agencies and others develop better policies for regulating gabapentinoids and treating opioid misuse and overdose. Supported by USPHS grant R01DA058018 and the Welch Foundation (Grant AQ-0039).

Self-Administration of Fentanyl-Alprazolam Combinations by Rhesus Monkeys Responding under a Progressive-Ratio Schedule

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys

Alternative Reinforcers Enhance the Effects of Opioid Antagonists, but Not Agonists, on Oxycodone Choice Self-Administration in Nonhuman Primates

Xylazine does not enhance fentanyl reinforcement in rats: a behavioral economic analysis

Fentanyl self‐administration is accelerated by methamphetamine co‐use and results in worsened hypodopaminergia in male, but not female rats

Self-Administration of Benzodiazepines in Drug-Naïve Rhesus Monkeys: Role of GABAA Receptor Subtypes

Effects of xylazine on naloxone-precipitated fentanyl withdrawal in male and female rats

Role of Mu-Opioid Agonist Efficacy on Antinociceptive Interactions Between Mu Agonists and the Nociceptin Opioid Peptide Agonist Ro 64-6198 in Rhesus Monkeys.

Effects of fentanyl and the adulterant levamisole on the rewarding and locomotor effects of methamphetamine in rats

Self-administration of progesterone and synthetic neuroactive steroids by male rhesus monkeys

Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ-Opioid Receptor.

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

Behavioral effects of triazolam and pregnanolone combinations: reinforcing and sedative-motor effects in female rhesus monkeys

Effects of gabapentinoids in male rats discriminating fentanyl from saline

Biological sex modulates the efficacy of 2,5-dimethoxy-4-iodoamphetamine (DOI) to mitigate fentanyl demand

The Hypnotic Synergism among a Water-Soluble Prodrug of Propofol,Midazolam and Fentanyl

Fentanyl activates opposing opioid and non-opioid receptor systems that control breathing

The effects of chronic neuropathic pain on the self-administration of highly potent MOR agonist, fentanyl

Targeting α1- and α2-adrenergic receptors as a countermeasure for fentanyl-induced locomotor and ventilatory depression

Dose- and Sex-Dependent Bidirectional Relationship between Intravenous Fentanyl Self-Administration and Gut Microbiota